The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -3,948,165 | -7,508,117 |
| Stock based compensation | 182,188 | 681,843 |
| Amortization of intangibles | 25,000 | 50,000 |
| Realized and unrealized gain and accrued interest on investments | -2,185 | 140,996 |
| Increase (decrease) in accounts payable and accrued expenses | 1,427,052 | 156,567 |
| Decrease in prepaid expenses and other assets | -86,281 | -480,193 |
| Net cash used in operating activities | -2,225,459 | -6,280,510 |
| Proceeds from redemption of investments | 2,537,873 | 4,452,701 |
| Net cash provided by investing activities | 2,537,873 | 4,452,701 |
| Payment of amounts due to officers | 150,000 | 300,000 |
| Proceeds from sale of equity securities, net | 0 | 172,958 |
| Net cash (used in) provided by financing activities | -150,000 | -127,042 |
| Net change in cash and cash equivalents | 162,414 | -1,954,851 |
| Cash and cash equivalents at beginning of period | 3,623,343 | - |
| Cash and cash equivalents at end of period | 1,830,906 | - |
Quoin Pharmaceuticals, Ltd. (QNRX)
Quoin Pharmaceuticals, Ltd. (QNRX)